New Formulations for Oral, Nasal, Transdermal and Rectal Delivery of Cannabinoids
|
Categories |
Cannabinoid Administration, Formulation, Drug Delivery, Novel Carriers, Transdermal Formulation, Nasal Formulation, Oral formulation |
|
Development Stage |
In-vivo proof of concept |
|
Patent Status |
Several patent applications – new technologies for various routes of administration |
|
Market |
Improved effect of Cannabinoids which are administrated via different routes is a real need and has increasing demand |
Background
-
There is a need for cannabinoids based products for treatment via various ways of administration (Nasal, Oral, Transdermal and Rectal), that are efficient and safe and show prolonged effective action.
-
Currently, cannabinoids are administrated in capsules or sublingual spray and the drug has only short action (a peak effect up to 4 hours with a median T max up to 2.5 hours).
-
Cannabinoids are very lipophilic molecules. Hence, in order to bring them to a molecular state (dissolved)-- solvents like vegetable oils, glycols (propylene glycol) and ethanol are used.
-
We have designed innovative cannabinoid formulations along the main routes of drug administration (dermal, nasal, oral and rectal) for treatment of various ailments: pain, neurological diseases, sleep, appetite, mood, anxiety, rheumatic arthritis, inflammatory diseases, and stress.
Highlights
-
Our new platform technologies for cannabinoids do not require oils or chemical solvents.
-
Eco-friendly preparation process with no need of high heating or use of solvents.
-
The inactive ingredients used in this new dosage form are approved for pharmaceutical use.
-
The technology is adequate for various cannabinoids: CBD, THC, iso-THC, CBG, CBC, CBN, CBE, CBL, CBT and their mixtures or for plant extracts.
-
In-vivo proof of concept
Our Innovation
Innovative formulations and compositions for design and development of new cannabinoid products for treatment of a wide range of diseases.
Key Features
-
Innovative transdermal, nasal, oral and rectal technologies for the development of new efficient products of cannabinoids (CBD, THC, others) for treatment of various diseases
-
IP
-
Excipients approved for pharmaceutical use
-
Eco-friendly processes
-
Experiments in a pain using an animal model that adminestered cannabinoids in the new oral formulation show a very efficient and prolonged antinociceptive effect.
Development Milestones
Seeking investment in new company or industrial collaboration for product development and clinical studies
Patent Status
Published US 2020/0197357 A1; CN108366962